Observational studyJournal of cancer research and clinical oncology2026
De-escalating axillary surgery in early breast cancer: external validation of a retrospective cohort.
Observational study in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSentinel lymph node biopsy (SLNB) is the standard for axillary staging in early breast cancer, yet its relevance is increasingly questioned in patients with favorable tumor biology when nodal status does not influence systemic treatment decisions.
methodsWe conducted a retrospective, single-center observational study including 162 women with clinically and sonographically node-negative (cN0) pT1 invasive breast cancer treated between 2019 and 2024 at a French university hospital. All patients underwent axillary staging and had complete molecular profiling. Among the 25 patients with pathologically positive nodes (pN+), two multidisciplinary team (MDT) discussions were simulated: one blinded to nodal status (limited-information MDT) and one with complete clinicopathologic data (full-information MDT). Recommendations for adjuvant chemotherapy and genomic testing (Oncotype DX) were compared.
resultsMost tumors were hormone receptor-positive (90%) and HER2-negative (87%); 9% were triple-negative. Despite negative preoperative axillary ultrasound, nodal involvement was identified in 25 patients (15%). In the limited-information MDT, chemotherapy was recommended in 8 patients and genomic testing in 11 patients. In contrast, the full-information MDT recommended chemotherapy in 16 patients and genomic testing in 9 patients, with 2 additional patients ultimately receiving chemotherapy. Omission of nodal status during MDT deliberation was associated with a significant reduction in chemotherapy recommendations (p < 0.01). Genomic testing contributed to treatment de-escalation in both scenarios.
conclusionsIn selected patients with pT1 breast cancer, omission of axillary nodal status during MDT decision-making may safely reduce adjuvant chemotherapy use without compromising treatment planning, supporting current axillary de-escalation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.